pyk2 inhibitor Search Results


pf431396 (potent pyrimidine-based pyk2 inhibitor) [3 μ m]  (Symansis Inc)
90
Symansis Inc pf431396 (potent pyrimidine-based pyk2 inhibitor) [3 μ m]
Pf431396 (Potent Pyrimidine Based Pyk2 Inhibitor) [3 μ M], supplied by Symansis Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pyk2+inhibitor/pyk2+inhibitor+pf431396/pmc03745320-65-35-46
Average 90 stars, based on 1 article reviews
pf431396 (potent pyrimidine-based pyk2 inhibitor) [3 μ m] - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
selective fak inhibitor pf-562271  (SYNkinase)
90
SYNkinase selective fak inhibitor pf-562271
Selective Fak Inhibitor Pf 562271, supplied by SYNkinase, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pyk2+inhibitor/pyk2+fak+specific+inhibitor/10__1158_slash_1078___0432__ccr___17___0375-56-8-11
Average 90 stars, based on 1 article reviews
selective fak inhibitor pf-562271 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
fak/pyk2 dual inhibitor pf-562,271  (ApexBio)
90
ApexBio fak/pyk2 dual inhibitor pf-562,271
(A) FAK and <t>phospho-PYK2</t> (p-PYK2) protein levels were analyzed by western blot in cortical bone isolated from femur and tibia of 1-month-old Fakflox/flox (Control) and Fakflox/flox;Col3.6-Cre (CKOCol3.6) male mice. (B) Representative image of 7-week-old control and CKOCol3.6 mice. (C) Body weight of male control and CKOCol3.6 mice at indicated ages (n=16, 26, 22, 17, 10, 6 in 1 week, 2 weeks, 3 weeks, 4 weeks, 7 weeks and 6 months groups respectively for control mice; and n=22, 34, 23, 17, 9, 8 in 1 week, 2 weeks, 3 weeks, 4 weeks, 7 weeks and 6 months groups respectively for CKOCol3.6 mice). (D) Body length of 7-week-old male control and CKOCol3.6 mice (n=14 for control mice, n=10 for CKOCol3.6 mice). (E-L) MicroCT analysis of femoral trabecular and cortical bone in 2-month-old (2M) and 6-month-old (6M) male mice: (E) BV/TV, bone volume fraction; (F) Tb.N, trabecular number; (G) Tb.Th, trabecular thickness; (H) Tb.Sp, trabecular spacing; (I) Ct.Th, average cortical thickness; (J) Ct.Ar, cortical bone area; (K) Ec.Pm, endocortical perimeter; (L) Ps.Pm, periosteal perimeter (n=15 and 5 in 2M and 6M groups respectively for control mice, n=16 and 8 in 2M and 6M groups respectively for CKOCol3.6 mice). Values were presented as median and interquartile range.
Fak/Pyk2 Dual Inhibitor Pf 562,271, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pyk2+inhibitor/fak+pyk2+dual+inhibitor+pf+562+271/pmc07486225-62-9-15
Average 90 stars, based on 1 article reviews
fak/pyk2 dual inhibitor pf-562,271 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
pf 431396  (Bio-Techne corporation)
94
Bio-Techne corporation pf 431396
(A) FAK and <t>phospho-PYK2</t> (p-PYK2) protein levels were analyzed by western blot in cortical bone isolated from femur and tibia of 1-month-old Fakflox/flox (Control) and Fakflox/flox;Col3.6-Cre (CKOCol3.6) male mice. (B) Representative image of 7-week-old control and CKOCol3.6 mice. (C) Body weight of male control and CKOCol3.6 mice at indicated ages (n=16, 26, 22, 17, 10, 6 in 1 week, 2 weeks, 3 weeks, 4 weeks, 7 weeks and 6 months groups respectively for control mice; and n=22, 34, 23, 17, 9, 8 in 1 week, 2 weeks, 3 weeks, 4 weeks, 7 weeks and 6 months groups respectively for CKOCol3.6 mice). (D) Body length of 7-week-old male control and CKOCol3.6 mice (n=14 for control mice, n=10 for CKOCol3.6 mice). (E-L) MicroCT analysis of femoral trabecular and cortical bone in 2-month-old (2M) and 6-month-old (6M) male mice: (E) BV/TV, bone volume fraction; (F) Tb.N, trabecular number; (G) Tb.Th, trabecular thickness; (H) Tb.Sp, trabecular spacing; (I) Ct.Th, average cortical thickness; (J) Ct.Ar, cortical bone area; (K) Ec.Pm, endocortical perimeter; (L) Ps.Pm, periosteal perimeter (n=15 and 5 in 2M and 6M groups respectively for control mice, n=16 and 8 in 2M and 6M groups respectively for CKOCol3.6 mice). Values were presented as median and interquartile range.
Pf 431396, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pyk2+inhibitor/PF+431396/custom%404278%4032510326
Average 94 stars, based on 1 article reviews
pf 431396 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

Image Search Results


(A) FAK and phospho-PYK2 (p-PYK2) protein levels were analyzed by western blot in cortical bone isolated from femur and tibia of 1-month-old Fakflox/flox (Control) and Fakflox/flox;Col3.6-Cre (CKOCol3.6) male mice. (B) Representative image of 7-week-old control and CKOCol3.6 mice. (C) Body weight of male control and CKOCol3.6 mice at indicated ages (n=16, 26, 22, 17, 10, 6 in 1 week, 2 weeks, 3 weeks, 4 weeks, 7 weeks and 6 months groups respectively for control mice; and n=22, 34, 23, 17, 9, 8 in 1 week, 2 weeks, 3 weeks, 4 weeks, 7 weeks and 6 months groups respectively for CKOCol3.6 mice). (D) Body length of 7-week-old male control and CKOCol3.6 mice (n=14 for control mice, n=10 for CKOCol3.6 mice). (E-L) MicroCT analysis of femoral trabecular and cortical bone in 2-month-old (2M) and 6-month-old (6M) male mice: (E) BV/TV, bone volume fraction; (F) Tb.N, trabecular number; (G) Tb.Th, trabecular thickness; (H) Tb.Sp, trabecular spacing; (I) Ct.Th, average cortical thickness; (J) Ct.Ar, cortical bone area; (K) Ec.Pm, endocortical perimeter; (L) Ps.Pm, periosteal perimeter (n=15 and 5 in 2M and 6M groups respectively for control mice, n=16 and 8 in 2M and 6M groups respectively for CKOCol3.6 mice). Values were presented as median and interquartile range.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Article Title: FAK promotes early osteoprogenitor cell proliferation by enhancing mTORC1 signaling

doi: 10.1002/jbmr.4029

Figure Lengend Snippet: (A) FAK and phospho-PYK2 (p-PYK2) protein levels were analyzed by western blot in cortical bone isolated from femur and tibia of 1-month-old Fakflox/flox (Control) and Fakflox/flox;Col3.6-Cre (CKOCol3.6) male mice. (B) Representative image of 7-week-old control and CKOCol3.6 mice. (C) Body weight of male control and CKOCol3.6 mice at indicated ages (n=16, 26, 22, 17, 10, 6 in 1 week, 2 weeks, 3 weeks, 4 weeks, 7 weeks and 6 months groups respectively for control mice; and n=22, 34, 23, 17, 9, 8 in 1 week, 2 weeks, 3 weeks, 4 weeks, 7 weeks and 6 months groups respectively for CKOCol3.6 mice). (D) Body length of 7-week-old male control and CKOCol3.6 mice (n=14 for control mice, n=10 for CKOCol3.6 mice). (E-L) MicroCT analysis of femoral trabecular and cortical bone in 2-month-old (2M) and 6-month-old (6M) male mice: (E) BV/TV, bone volume fraction; (F) Tb.N, trabecular number; (G) Tb.Th, trabecular thickness; (H) Tb.Sp, trabecular spacing; (I) Ct.Th, average cortical thickness; (J) Ct.Ar, cortical bone area; (K) Ec.Pm, endocortical perimeter; (L) Ps.Pm, periosteal perimeter (n=15 and 5 in 2M and 6M groups respectively for control mice, n=16 and 8 in 2M and 6M groups respectively for CKOCol3.6 mice). Values were presented as median and interquartile range.

Article Snippet: FAK kinase inhibitor PF-573,228 (# B1523, Apexbio Technology) or FAK/PYK2 dual inhibitor PF-562,271 (# A8320, Apexbio Technology) was added with different doses at different time points every other day.

Techniques: Western Blot, Isolation

(A) Representative western blot image showing that phospho-FAK (p-FAK) and phospho-PYK2 (p-PYK2) levels in BMSCs were dose-dependently suppressed by FAK/PYK2 dual inhibitor PF-562,271. (B-C) Quantification of the relative p-FAK level (B) and p-PYK2 level (C) illustrated in (A) (n=4). p-FAK and p-PYK2 levels were normalized by their respective total protein levels. (D) Cartoon showing the experimental design of FAK/PYK2 dual inhibitor PF-562,271 treatment used in (E-F). Dashed red line indicates no treatment, dashed black line indicates vehicle treatment and solid black line indicates 1 μM PF-562,271 treatment. D7-D11 means FAK/PYK2 dual inhibitor was added from day 7 to day 11. E) BMSCs were collected at day 11 and extracted proteins were analyzed by western blot using indicated antibodies. (F) Quantification of the relative protein level illustrated in (E). Phospho-proteins were normalized to the respective total proteins and β-catenin was normalized to Vinculin (n=3). Values were presented as median and interquartile range.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Article Title: FAK promotes early osteoprogenitor cell proliferation by enhancing mTORC1 signaling

doi: 10.1002/jbmr.4029

Figure Lengend Snippet: (A) Representative western blot image showing that phospho-FAK (p-FAK) and phospho-PYK2 (p-PYK2) levels in BMSCs were dose-dependently suppressed by FAK/PYK2 dual inhibitor PF-562,271. (B-C) Quantification of the relative p-FAK level (B) and p-PYK2 level (C) illustrated in (A) (n=4). p-FAK and p-PYK2 levels were normalized by their respective total protein levels. (D) Cartoon showing the experimental design of FAK/PYK2 dual inhibitor PF-562,271 treatment used in (E-F). Dashed red line indicates no treatment, dashed black line indicates vehicle treatment and solid black line indicates 1 μM PF-562,271 treatment. D7-D11 means FAK/PYK2 dual inhibitor was added from day 7 to day 11. E) BMSCs were collected at day 11 and extracted proteins were analyzed by western blot using indicated antibodies. (F) Quantification of the relative protein level illustrated in (E). Phospho-proteins were normalized to the respective total proteins and β-catenin was normalized to Vinculin (n=3). Values were presented as median and interquartile range.

Article Snippet: FAK kinase inhibitor PF-573,228 (# B1523, Apexbio Technology) or FAK/PYK2 dual inhibitor PF-562,271 (# A8320, Apexbio Technology) was added with different doses at different time points every other day.

Techniques: Western Blot

The model depicts the mechanisms of FAK action at three distinct stages of osteoblast lineage in which the roles of FAK have been addressed by genetic and pharmacological approaches as well as the respective Cre transgenes used to delete Fak, including Dermo1-Cre (this study), Osterix-Cre,(10) Col3.6-Cre (this study) and Col2.3-Cre.(9) Red ↔ indicates that the loss of FAK in osteoblasts can be compensated by the upregulated active PYK2.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Article Title: FAK promotes early osteoprogenitor cell proliferation by enhancing mTORC1 signaling

doi: 10.1002/jbmr.4029

Figure Lengend Snippet: The model depicts the mechanisms of FAK action at three distinct stages of osteoblast lineage in which the roles of FAK have been addressed by genetic and pharmacological approaches as well as the respective Cre transgenes used to delete Fak, including Dermo1-Cre (this study), Osterix-Cre,(10) Col3.6-Cre (this study) and Col2.3-Cre.(9) Red ↔ indicates that the loss of FAK in osteoblasts can be compensated by the upregulated active PYK2.

Article Snippet: FAK kinase inhibitor PF-573,228 (# B1523, Apexbio Technology) or FAK/PYK2 dual inhibitor PF-562,271 (# A8320, Apexbio Technology) was added with different doses at different time points every other day.

Techniques: